ConductScience.org, home

Paper41249657

Improving surgical treatments for hepatocellular carcinoma.

Malik AK and 5 others. Nat Rev Gastroenterol Hepatol, 2026. Cited by 14 papers, by iCite.

Cite this record

ConductScience Library. Improving surgical treatments for hepatocellular carcinoma. Papers, record 41249657. Release papers-2026-11-12-0.1.0, 12 Nov 2026. https://conductscience.org/library/papers/41249657

Download JSON
Sources
11 sources
Release
papers-2026-11-12-0.1.0

Paper

PubMed's record of the paper, with iCite's citation figures. No abstract is shown.

Title
Improving surgical treatments for hepatocellular carcinoma.
PubMed
Journal
Nat Rev Gastroenterol Hepatol
PubMed
Year
2026
PubMed
Publication types
Journal Article, Review
PubMed
Citations, by iCite
14
iCite
Relative citation ratio, by iCite
8.03, provisional
iCite
Revised in PubMed
2026-11-03
PubMed

Authors6

The authors in the order PubMed's record lists them, with the ORCID iDs it states.

OrderAuthorForenameKindORCID iD
1Malik AKAbdullah Khttps://orcid.org/0000-0003-2922-254X
2Geh DDaniel
3Jeffry Evans TRThomas R
4Chow PKHPierce K Hhttps://orcid.org/0000-0003-0584-2584
5Mann DADerek Ahttps://orcid.org/0000-0003-0950-243X
6White SASteven A

Source PubMed

Download CSV of authors

Topics9

NLM's MeSH indexing of the paper, its major topics first.

MeSH termMajor
Carcinoma, HepatocellularMajor topic
Liver NeoplasmsMajor topic
Humans
Neoplasm Recurrence, Local
Hepatectomy
Liver Transplantation
Neoadjuvant Therapy
Immunotherapy
Precision Medicine

Source PubMed

Download CSV of topics

References248

The papers the reference list in PubMed's record names, those in our copy of PubMed, in the list's order.

OrderPMIDTitleJournalYearIn PapersSource
128299619Double- and Triple-Positive Tumor Markers Predict Early Recurrence and Poor Survival in Patients with Hepatocellular Carcinoma within the Milan Criteria and Child-Pugh Class A.J Gastrointest Surg2017https://conductscience.org/library/papers/28299619PubMed
236810207Cost of hepatocellular carcinoma to the national health service in England: a registry-based analysis.BMJ Open Gastroenterol2023https://conductscience.org/library/papers/36810207PubMed
337683735AFP-L3 and DCP strongly predict early hepatocellular carcinoma recurrence after liver transplantation.J Hepatol2023https://conductscience.org/library/papers/37683735PubMed
431550417Fatal hepatic necrosis after nivolumab as a bridge to liver transplant for HCC: Are checkpoint inhibitors safe for the pretransplant patient?Am J Transplant2020https://conductscience.org/library/papers/31550417PubMed
539255928Intention-to-treat outcomes of patients with hepatocellular carcinoma receiving immunotherapy before liver transplant: The multicenter VITALITY study.J Hepatol2025https://conductscience.org/library/papers/39255928PubMed
635258511Liver Transplantation Outcomes From Controlled Circulatory Death Donors: SCS vs in situ NRP vs ex situ NMP.Ann Surg2022https://conductscience.org/library/papers/35258511PubMed
718650514Sorafenib in advanced hepatocellular carcinoma.N Engl J Med2008https://conductscience.org/library/papers/18650514PubMed
837208105Machine perfusion of the liver and bioengineering.J Hepatol2023https://conductscience.org/library/papers/37208105PubMed
928371119Rapamycin inhibits the secretory phenotype of senescent cells by a Nrf2-independent mechanism.Aging Cell2017https://conductscience.org/library/papers/28371119PubMed
1029798856Gut microbiome-mediated bile acid metabolism regulates liver cancer via NKT cells.Science2018https://conductscience.org/library/papers/29798856PubMed
1136450386Nivolumab after selective internal radiation therapy for the treatment of hepatocellular carcinoma: a phase 2, single-arm study.J Immunother Cancer2022https://conductscience.org/library/papers/36450386PubMed
1228473688Long-Term Outcome of Liver Resection Versus Transplantation for Hepatocellular Carcinoma in a Region Where Living Donation is a Main Source.Ann Transplant2017https://conductscience.org/library/papers/28473688PubMed
1332695968New frontiers in liver resection for hepatocellular carcinoma.JHEP Rep2020https://conductscience.org/library/papers/32695968PubMed
1436470717Application of hazard functions to investigate recurrence after curative-intent resection for hepatocellular carcinoma.HPB (Oxford)2023https://conductscience.org/library/papers/36470717PubMed
1523108125Resection or transplantation for early hepatocellular carcinoma in a cirrhotic liver: does size define the best oncological strategy?Ann Surg2012https://conductscience.org/library/papers/23108125PubMed
1633800224Influence of Hepatocellular Carcinoma on Platelet Aggregation in Cirrhosis.Cancers (Basel)2021https://conductscience.org/library/papers/33800224PubMed
1735120736Baveno VII - Renewing consensus in portal hypertension.J Hepatol2022https://conductscience.org/library/papers/35120736PubMed
1836124430mTORi-based immunosuppression reduces HCC recurrence at the expense of increased adverse side effects: A systematic review and meta-analysis.Clin Transplant2022https://conductscience.org/library/papers/36124430PubMed
1937351126Resection vs. transplantation for hepatocellular carcinoma: a never ending challenge.Hepatobiliary Surg Nutr2023https://conductscience.org/library/papers/37351126PubMed
2010094953Preoperative portal vein embolization: an audit of 84 patients.Hepatology1999https://conductscience.org/library/papers/10094953PubMed

See all 248 referencesDownload CSV of references

Cited by13

The papers in our copy of PubMed whose reference list names this one, newest first. iCite, which reads more sources, counts 14 citations.

PMIDTitleJournalYearIn PapersSource
42840030
An inflammation-nutrition-surgery-based INSEP model and a web-based clinical decision support system for predicting early postoperative infection in elderly patients with hepatocellular carcinoma: a multicenter retrospective study.
Front Nutr2026https://conductscience.org/library/papers/42840030PubMed
42767769NKG2A-HLA-E axis contributes to an immunosuppressive checkpoint network in hepatocellular carcinoma.J Immunother Cancer2026https://conductscience.org/library/papers/42767769PubMed
42709244Effects of inhaled lavender essential oil on sleep quality, pain, and anxiety in ICU patients after curative hepatocellular carcinoma resection: a quasi-experimental study.Support Care Cancer2026https://conductscience.org/library/papers/42709244PubMed
42683256Mac-2 Binding Protein Glycosylation Isomer (M2BPGi)-Based Risk Stratification Refined by Tumor Metabolic Activity in Hepatocellular Carcinoma.Ann Gastroenterol Surg2026https://conductscience.org/library/papers/42683256PubMed
42581040
Temperature-sensitive liquid embolic agent transarterial chemoembolization versus drug-eluting bead transarterial chemoembolization for BCLC Stage B/C hepatocellular carcinoma: a multicenter real-world study and spatial transcriptomics profiling (CHANCE 2515).
Signal Transduct Target Ther2026https://conductscience.org/library/papers/42581040PubMed
42548727Integrative Multiomics Analysis Reveals a Cancer Stem Cell-Driven Prognostic Signature and Nominates Belinostat for Targeted Therapy in Hepatocellular Carcinoma.Stem Cells Int2026https://conductscience.org/library/papers/42548727PubMed
42404398
Development and Validation of a Six-Gene Signature of Myeloid Antigen Presentation Dysfunction Based on Single-Cell and Multi-Cohort Transcriptomics for Predicting Prognosis and Recurrence of Hepatocellular Carcinoma.
Cancer Inform2026https://conductscience.org/library/papers/42404398PubMed
42404106Emerging Role of Sirtuins-Mediated Ferroptosis in Hepatocellular Carcinoma Progression: Mechanisms and Therapeutic Perspectives.J Hepatocell Carcinoma2026https://conductscience.org/library/papers/42404106PubMed
42365459Independent Prognosis Prediction of Hepatocellular Carcinoma Using MicroRNA-Based Single and Combined Biomarkers.Can J Gastroenterol Hepatol2026https://conductscience.org/library/papers/42365459PubMed
42005557Global Advances in Hepatocellular Carcinoma Research and Therapy in 2025.Cancer Innov2026https://conductscience.org/library/papers/42005557PubMed
41953857Understanding Liver and Digestive Diseases: A Paved Road to Improve Diagnosis, Management, and Treatment.Explor Dig Dis2026https://conductscience.org/library/papers/41953857PubMed
41913379Surgery-centered integrated strategies for personalized hepatocellular carcinoma care.Cancer Biol Med2026https://conductscience.org/library/papers/41913379PubMed
41873435Construction and Validation of a Predictive Model for Post-TACE Recurrence Risk in Hepatocellular Carcinoma: A Retrospective Cohort Study.J Hepatocell Carcinoma2026https://conductscience.org/library/papers/41873435PubMed

Download CSV of cited by

Data dates

The date of each source this release read.

PubMed
2026-11-06
PubMed
iCite
2026-11-05
iCite
PMC's ID file
2026-11-05
PMC's ID file
NIH RePORTER's grant and paper links
2026-11-01
NIH RePORTER's grant and paper links
Trials
2026-11-12
Gene search
2026-11-11
Pipelines
2026-09-18

None in this release

  • Grants
  • Trials
  • Comments and corrections
  • Genes
  • Drugs
  • Data

Sources 11

  • ChEMBL, through Open TargetsCC BY-SA 3.0
  • ClinicalTrials.govNo license stated
  • HGNCCC0
  • iCiteCC BY 4.0
  • NCBI GenePublic domain (US government)
  • NIH RePORTER's grant and paper linksPublic domain
  • Open TargetsCC0 1.0
  • PMC's ID filePublic domain (US government)
  • PubMedNLM's terms
  • PubTator 3Public domain
  • UniProtCC BY 4.0
Each source's terms
  • ChEMBL, through Open TargetsCC BY-SA 3.0, for the parts from ChEMBL. Read on 8 Nov 2026 at https://platform-docs.opentargets.org/licence
  • ClinicalTrials.govnone stated
  • HGNCCC0: https://www.genenames.org/about/license/
  • iCiteCC BY 4.0
  • NCBI GeneNone named for the file. NCBI says information created by or for the US government on its site is in the public domain, and asks that NLM be acknowledged: https://www.ncbi.nlm.nih.gov/home/about/policies/
  • NIH RePORTER's grant and paper linksPublic domain (NIH RePORTER)
  • Open TargetsCC0 1.0. Open Targets asks that users cite its latest paper: Buniello et al. 2025, Open Targets Platform: facilitating therapeutic hypotheses building in drug discovery, Nucleic Acids Research 53(D1):D1467, PMID 39657122. Read on 8 Nov 2026 at https://platform-docs.opentargets.org/licence
  • PMC's ID fileNone named for the file. NCBI says information created by or for the US government on its site is in the public domain, and asks that NLM be acknowledged: https://www.ncbi.nlm.nih.gov/home/about/policies/
  • PubMedNLM's terms
  • PubTator 3Public domain
  • UniProtCC BY 4.0. UniProt's licence file: "All databases and documents in the UniProt FTP directory may be copied and redistributed freely, without advance permission, provided that this copyright statement is reproduced with each copy." UniProt asks that users cite its latest paper: The UniProt Consortium, UniProt: the Universal Protein Knowledgebase in 2025, Nucleic Acids Research 53:D609-D617, https://doi.org/10.1093/nar/gkae1010. Read on 9 Nov 2026 at https://www.uniprot.org/help/license

ClinicalTrials.gov's data carry an international copyright outside the United States: https://clinicaltrials.gov/about-site/terms-conditions.

For software

Read this paper from software.

The record and each of its lists are JSON, twenty rows a page. No key.

GET https://conductscience.org/api/papers/v1/41249657

GET https://conductscience.org/api/papers/v1/41249657/references?page=2